r-tPA

Phase 1Small molecule

TThrombolex, Inc.

r-tPA is one of 26 small molecule programs targeting Pulmonary Embolism. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pulmonary EmbolismCompleted

Pulmonary EmbolismPhase 1

Completed

Competition

Competitive Landscape

27 competitors in Pulmonary Embolism

#DrugCompanyPhaseTrials

Activase

Roche

Approved

8 2

Eliquis

Bristol-Myers Squibb

Approved

2 3

Bayer Aspirin

Bayer

Approved

1 4

Innohep

Jazz Pharmaceuticals

Approved

1 5

Xarelto

WWim Janssens

Approved

8 6

Coumadin

AAbbott

Approved

6 7

Savaysa

Voltaren

Opsumit

Pradaxa

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

PreclinicalRecruiting

Pulmonary Embolism

NCT06433011

Clinical

Trials by Indication[1]

Pulmonary Embolism2 trials

First - In - Man Study to Assess the Safety and Feasibility of The Bashir™ Endovascular Catheter for the Treatment of Acute Pulmonary Embolism

Completed·TThrombolex, Inc.·Phase 1·NCT03927508·9 enrolled

The RAPID - PE Study: RESCUE Advanced Protocol Without ICU Stay and no Lytic Drip - for the Treatment of Pulmonary Embolism

Recruiting·TThrombolex, Inc.·Preclinical·NCT06433011·500 enrolled

Treatment1 trial

tPA by Endovascular Administration for the Treatment of Submassive PE Using CDT for the Reduction of Thrombus Burden

Completed·TThrombolex, Inc.·Phase 3·NCT04248868·109 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for r-tPA. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — r-tPA compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for r-tPA. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Thrombolex, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: TThrombolex, Inc.

r-tPA

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Pulmonary Embolism2 trials

Treatment1 trial

References

Drug Info

Quick Facts

Related News